BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data

Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...

June 15, 2026 | News

Akeso Expands Immunology Franchise with Approval of Gumokimab for Psoriasis

Akeso, Inc. announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-devel...

June 15, 2026 | News

Formation Bio Doses First Participant in Phase I Trial of Lynk’s CNS-Penetrant TYK2 Inhibitor

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseas...

June 12, 2026 | News

Harbour BioMed Secures China IND Acceptance for Novel Bispecific Cancer Therapy HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

June 12, 2026 | News

China Clears Adcentrx’s ADRX 0405 For Clinical Development In Advanced Solid Tumours

Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...

June 10, 2026 | News

Vcare PharmaTech Secures China Approval for Next Generation TRK Inhibitor Eratrectinib in NTRK Fusion Positive Solid Tumours

NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the...

June 08, 2026 | News

ImmVira Reports 100% Complete Response Rate With MVR T3011 In BCG Unresponsive Bladder Cancer

ImmVira Group announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 Ameri...

June 02, 2026 | News

Dizal Secures Priority Review In China For ZEGFROVY In First Line EGFR Exon20ins NSCLC

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced...

May 29, 2026 | News

Kazia Therapeutics Expands Paxalisib TNBC Trial Following Encouraging Early Safety Data

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data Kazia Therapeutics Limited (NASDAQ...

May 28, 2026 | News

Nuance Pharma Secures NMPA Clearance For Pivotal Actair® Allergy Trial In China

NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients Nuance Pharma announced that the National Medical...

May 25, 2026 | News

Leads Biolabs Secures China Phase III Approval For Opamtistomig In First Line EP NEC Treatment

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibod...

May 20, 2026 | News

ImmunityBio Secures Exclusive US Rights To Tokyo Strain BCG To Address Chronic Bladder Cancer Treatment Shortage

Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo...

May 19, 2026 | News

Racura Oncology Receives Positive Safety Review Committee Recommendation To Advance CPACS Trial In Advanced Solid Tumours

Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced soli...

May 18, 2026 | News

Sichuan Kelun-Biotech Biopharmaceutical Secures China IND Clearance For PD 1 x VEGF Bispecific SKB118 In Advanced Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...

May 14, 2026 | News

Stay Connected